Driving under the influence of synthetic phenethylamines: a case series

International Journal of Legal Medicine

Volumn 129, Issue 5, 2015, Pages 997-1003

  Maas, Alexandra ^a   Wippich, Cornelia ^a   Madea, Burkhard ^a   Hess, Cornelius ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Driving under the influence of drugs (DUID); Synthetic cathinones; Synthetic phenethylamines; Bath salts ; Legal highs

Indexed keywords

DESIGNER DRUG; PHENETHYLAMINE DERIVATIVE;

ADULT; BLOOD; CASE REPORT; CHEMICAL STRUCTURE; CHEMISTRY; DRUNKEN DRIVING; FORENSIC TOXICOLOGY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS FRAGMENTOGRAPHY; SUBSTANCE ABUSE; YOUNG ADULT;

ADULT; CHROMATOGRAPHY, LIQUID; DESIGNER DRUGS; DRIVING UNDER THE INFLUENCE; FORENSIC TOXICOLOGY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MOLECULAR STRUCTURE; PHENETHYLAMINES; SUBSTANCE ABUSE DETECTION; YOUNG ADULT;

EID: 84940449784     PISSN: 09379827     EISSN: 14371596     Source Type: Journal    
DOI: 10.1007/s00414-015-1150-1     Document Type: Article

References (38)

1. Gibbons S, Zloh M (2010) An analysis of the “legal high” mephedrone. Bioorg Med Chem Lett 20:4135–4139
2. Buchanan JF, Brown CR (1988) “Designer drugs”. A problem in clinical toxicology. Med Toxicol Adverse Drug Exp 3:1–17
3. Cozzi N, Sievert M, Shulgin T, Jacob P, Ruoho E (1999) Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 381:63–69
4. Nagai F, Nonaka R, Satoh Hisashi Kamimura K (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132–137
5. Zaitsu K, Katagi M, Tatsuno M, Sato T, Tsuchihashi H, Suzuki K (2011) Recently abused β-keto derivatives of 3,4-methylenedioxyphenylalkylamines: a review of their metabolisms and toxicological analysis. Forensic Toxicol 29:73–84
6. Weilemann LS (2013) Not all drugs are the same. Med Klin Intensivmed Notfmed 108:484–490
7. Banks ML, Worst TJ, Rusyniak DE, Sprague JE (2014) Synthetic cathinones (“bath salts”). J Emerg Med 46:632–642
8. Mas-Morey P, Visser MHM, Winkelmolen L, Touw DJ (2013) Clinical toxicology and management of intoxications with synthetic cathinones (“bath salts”). J Pharm Pract 26:353–357
9. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F (2011) Mephedrone, new kid for the chop? Addiction 106:154–161
10. Newcombe R (2009) Mephedrone: use of Mephedrone (M-cat, meow) in Middlesbrough. UK Lifeline Publ., Manchester
11. European Monitoring Centre for Drugs and Drug Addiction (2011) Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances. EMCDDA, Lisabon, Risk assessments 9
12. Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33–42
13. Spiller HA, Ryan ML, Weston RG, Jansen J (2011) Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol (Phila) 49:499–505
14. Marinetti LJ, Antonides HM (2013) Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol 37:135–146
15. Schifano F, Albanese A, Fergus S et al (2011) Mephedrone (4-methylmethcathinone; “meow meow”): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 214:593–602
16. Musshoff F, Madea B, Kernbach-Wighton G, Bicker W, Kneisel S, Hutter M, Auwärter V (2014) Driving under the influence of synthetic cannabinoids (“Spice”): a case series. Int J Legal Med 128:59–64
17. Brunt TM, Poortman A, Niesink RJM, van den Brink W (2011) Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 25:1543–1547
18. Ratnapalan S (2013) Legal substances and their abuse: legal highs. J Paramed Pract 5:40–51
19. Wood DM, Davies S, Greene SL, Button J, Holt DW, Ramsey J, Dargan PI (2010) Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila) 48:924–927
20. Mugele J, Nañagas K, Tormoehlen LM (2012) Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med 60:100–102
21. Elliott S, Evans J (2014) A 3-year review of new psychoactive substances in casework. Forensic Sci Int 243C:55–60
22. Helander A, Bäckberg M, Hultén P, Al-Saffar Y, Beck O (2014) Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. Forensic Sci Int 243C:23–29
23. European Monitoring Centre for Drugs and Drug Addiction (2012) Annual report on the state of the drugs problem in Europe. EMCDDA, Lisabon
24. Peters FT, Hartung M, Herbold M, Schmitt G, Daldrup T, Mußhoff F (2009) Anhang B - Anforderungen an die Validierung von Analysenmethoden. Toxichem Krimtech 79:185–208
25. Deluca P, Schifano F, Davey Z et al (2010) Mephedrone report. Psychonaut Web Mapp. Res. Group, London
26. Coppola M, Mondola R (2012) 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208:12–15
27. Knoy JL, Peterson BL, Couper FJ (2014) Suspected impaired driving case involving a-pyrrolidinovalerophenone, methylone and ethylone. J Anal Toxicol 38:615–617
28. Johansen SS, Hansen TM (2012) Isomers of fluoroamphetamines detected in forensic cases in Denmark. Int J Legal Med 126:541–547
29. Röhrich J, Becker J, Kaufmann T, Zörntlein S, Urban R (2012) Detection of the synthetic drug 4-fluoroamphetamine (4-FA) in serum and urine. Forensic Sci Int 215:3–7
30. Zuba D, Byrska B (2013) Prevalence and co-existence of active components of “legal highs”. Drug Test Anal 5:420–429
31. Davies S, Wood DM, Smith G, Button J, Ramsey J, Archer R, Holt DW, Dargan PI (2010) Purchasing “legal highs” on the Internet—is there consistency in what you get? QJM 103:489–493
32. Westphal F, Rösner P, Junge T (2010) Differentiation of regioisomeric ring-substituted fluorophenethylamines with product ion spectrometry. Forensic Sci Int 194:53–59
33. Logan BK (2002) Methamphetamine—effects on human performance and behavior. Forensic Sci Rev 14:133–151
34. Anzenbacher P, Zanger U (2012) Metabolism of drugs and other xenobiotics. John Wiley & Sons
35. Caldwell J (1976) The metabolism of amphetamines in mammals. Drug Metab Rev 5:219–280
36. Deluca P, Schifano F, Davey Z et al (2009) MDPV report. Psychonaut Web Mapp. Res. Group, London
37. Couper FJ, Chopra K, Pierre-Louis MLY (2005) Fatal methadone intoxication in an infant. Forensic Sci Int 153:71–73
38. Aschenbrenner DS, Venable SJ (2009) Drug therapy in nursing. Lippinicott, Williams & Wilkins, Philadelphia